Get the Stockscreener App
6.79
4.77%
-0.34
After Hours:
6.98
0.19
+2.80%
Mind Medicine Inc stock is traded at $6.79, with a volume of 1.15M.
It is down -4.77% in the last 24 hours and down -2.44% over the past month.
Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.
See More
Previous Close:
$7.13
Open:
$7.15
24h Volume:
1.15M
Relative Volume:
0.81
Market Cap:
$497.92M
Revenue:
$11.40B
Net Income/Loss:
$-95.73M
P/E Ratio:
-2.7714
EPS:
-2.45
Net Cash Flow:
$-64.37M
1W Performance:
-2.86%
1M Performance:
-2.44%
6M Performance:
-26.67%
1Y Performance:
+75.91%
1-Day Range:
$6.79
$7.32
1-Week Range:
$6.75
$7.70
52-Week Range:
$3.82
$12.22
Mind Medicine Inc Stock (MNMD) Company Profile
Name
Mind Medicine Inc
Sector
Industry
Phone
212-220-6633
Address
ONE WORLD TRADE CENTER, NEW YORK
Compare MNMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNMD
Mind Medicine Inc
|
6.79 | 497.92M | 11.40B | -95.73M | -64.37M | -2.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Evercore ISI | Outperform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Jul-24-24 | Initiated | ROTH MKM | Buy |
| May-29-24 | Initiated | Robert W. Baird | Outperform |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | Canaccord Genuity | Buy |
| Dec-09-22 | Resumed | ROTH Capital | Buy |
| Nov-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-26-22 | Initiated | Oppenheimer | Outperform |
| Aug-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-04-22 | Initiated | ROTH Capital | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
View All
Mind Medicine Inc Stock (MNMD) Latest News
HC Wainwright Reiterates "Buy" Rating for Mind Medicine (MindMed) (NASDAQ:MNMD) - MarketBeat
Leerink Partnrs Has Bearish Outlook for MNMD Q4 Earnings - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Equities Analysts Set Expectations for MNMD Q1 Earnings - Defense World
MindMed Initiates Second Phase 3 Study of MM120 for Anxiety - TipRanks
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Gap UpHere's Why - MarketBeat
What is Leerink Partnrs' Forecast for MNMD Q1 Earnings? - MarketBeat
MindMed launches phase 3 trial for anxiety treatment - Investing.com
MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder - bastillepost.com
(MNMD) Trading Signals - Stock Traders Daily
MindMed's LSD Anxiety Drug: Revisiting, Rethinking, But Maintaining My 'Hold' Call (MNMD) - Seeking Alpha
Mind Medicine Stock Rises As Evercore Projects 200% Upside On LSD Formulation: Retail Turns Bullish - MSN
Mind Medicine (MindMed) (NASDAQ:MNMD) Now Covered by Evercore ISI - MarketBeat
Evercore ISI Group Initiates Coverage of Mind Medicine (MNMD) with Outperform Recommendation - MSN
Mind Medicine (MindMed) (NASDAQ:MNMD) Coverage Initiated by Analysts at Evercore ISI - MarketBeat
This Westlake Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
Why Mind Medicine Stock Is Soaring Today - MSN
Where are the Opportunities in (MNMD) - Stock Traders Daily
Mind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Up 6.4%What's Next? - MarketBeat
Wealth Enhancement Advisory Services LLC Acquires 2,230 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Defense World
Barclays PLC Has $775,000 Stake in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - MarketBeat
MindMed gives more detail to investors in latest presentation - Green Market Report
Psychedelic drug developer Lykos could get lifeline from former Tesla board member - Seeking Alpha
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Mind Medicine Inc Reports Topline Data from Phase 1 Trial of MM-110 in Development for Treatment of Opioid Withdrawal - Marketscreener.com
Institutional investors are Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) biggest bettors and were rewarded after last week's US$73m market cap gain - Simply Wall St
Mind Medicine (MindMed) (NASDAQ:MNMD) Trading 7.8% HigherShould You Buy? - MarketBeat
Mind Medicine (MindMed) (NASDAQ:MNMD) Trading Down 3.7%Should You Sell? - MarketBeat
MindMed to Participate in the Jefferies Global Healthcare Conference - Marketscreener.com
Geode Capital Management LLC Has $9.55 Million Stake in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Shares Purchased by Barclays PLC - MarketBeat
(MNMD) Investment Analysis - Stock Traders Daily
Mind Medicine's chief medical officer sells shares worth $49,357 - Investing.com India
Mind Medicine's chief medical officer sells shares worth $49,357 By Investing.com - Investing.com Australia
Mind Medicine CEO Robert Barrow sells shares worth $141,957 By Investing.com - Investing.com Nigeria
Mind Medicine's chief legal officer sells $33,576 in stock - Investing.com India
Mind Medicine CEO Robert Barrow sells shares worth $141,957 - Investing.com India
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) CEO Sells $141,957.58 in Stock - MarketBeat
Carrie Liao Sells 2,273 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Stock - MarketBeat
Mind medicine's chief accounting officer sells shares for $16,888 By Investing.com - Investing.com Canada
Mind Medicine’s chief medical officer sells shares worth $49,357 By Investing.com - Investing.com Nigeria
Mind Medicine's chief legal officer sells $33,576 in stock By Investing.com - Investing.com South Africa
Mind Medicine’s chief legal officer sells $33,576 in stock By Investing.com - Investing.com Nigeria
Mind Medicine (MindMed) (NASDAQ:MNMD) Trading Down 8.5%Here's Why - MarketBeat
Mind Medicine Inc Stock (MNMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.95%
2.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):